Treatment with the asthma medication montelukast may trigger eosinophilic granulomatosis with polyangiitis (EGPA), the rarest type of ANCA-associated vasculitis (AAV), a case-based review study suggests. The study, “Eosinophilic granulomatosis with polyangiitis and its association with montelukast: a case-based review,” was published in Clinical Rheumatology. AAV is a…
News
The U.S. Food and Drug Administration (FDA) has given Nkarta the green light to launch a clinical trial testing its cell therapy candidate NKX019 in people with ANCA-associated vasculitis (AAV) and other autoimmune disorders. The upcoming multicenter trial, dubbed Ntrust-2, is expected to initially recruit as many as…
Tavneos (avacopan) is better than the glucocorticoid prednisone at promoting disease remission, lowering relapse rates, and improving quality of life in ANCA-associated vasculitis (AAV) patients with active ear, nose, or throat (ENT) manifestations. That’s according to new subgroup analyses from the Phase 3 ADVOCATE clinical trial (NCT02994927).
Melodia Therapeutics has acquired the exclusive rights to develop, manufacture, and commercialize MDI-0151, a candidate therapy for hard-to-treat ANCA-associated vasculitis (AAV) and other disorders marked by overactivation of neutrophils, a type of immune cell. Melodia said it will “rapidly initiate” investigational new drug (IND)-enabling studies in preparation of a…
The U.S. Food and Drug Administration (FDA) has given NovelMed the green light to initiate a Phase 2 clinical trial to test its investigational antibody-based therapy ruxoprubart in adults with ANCA-associated vasculitis (AAV). The Phase 2 study (NCT06226662) will evaluate the therapy’s safety and efficacy in up…
Inflammatory bowel disease (IBD) — a chronic disease where the bowel becomes inflamed, causing recurring lower abdominal pain and diarrhea — can overlap with ANCA-associated vasculitis (AAV) and is often diagnosed first, a study found. The finding suggests a possible link between the two diseases, and that having IBD…
Symptoms and disease manifestations of eosinophilic granulomatosis with polyangiitis (EGPA), a rare type of ANCA-associated vasculitis (AAV), are generally similar between patients with and without ANCAs, the self-reactive antibodies that drive most AAV cases. That’s according to a study analyzing data from a registry of people with vasculitis, or…
Sinonasal manifestations — those encompassing the nose and the paranasal sinuses, or the air-filled cavities around the nose — in granulomatosis with polyangiitis (GPA) vary among patients, based on disease activity and duration. That’s according to a small, retrospective study of GPA patients with sinonasal manifestations seen at a…
About 1 in every 5 people with ANCA-associated vasculitis (AAV), at some point in life, may experience problems that keep the thyroid gland from making the right amount of hormones, with these problems most often developing within five years of an AAV diagnosis, a large study found. While…
High blood levels of the protein CX3CL1, a pro-inflammatory immune signal that appears to be associated with blood vessel inflammation, can accurately discriminate microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) patients with active disease from those without, a study found. Importantly, high CX3CL1 levels were found to increase the…
Recent Posts
- New analysis identifies phase-specific relapse risks in AAV treatment
- Sharing with others about vasculitis can strengthen connections
- New nanoparticle approach targets kidney damage in vasculitis
- Study points to 2 biomarkers for AAV disease activity, relapse
- Monitoring our kidney health is crucial with ANCA vasculitis